University of Münster (WWU)

University of Münster
The Westfaelische Wilhelms-Universitaet (WWU), Muenster, Germany, is the fourth largest university in Germany and is internationally recognised for its research focus on ECM, vascular biology, inflammation and both optical and medical imaging. This is reflected in several German Research Foundation funded collaborative research centres (CRCs/SFBs) in biomedicine, including Multiple Sclerosis (SFB TR 128), Immune Barriers (SFB 1009), Cell Dynamics (SFB 629), Molecular Imaging (SFB 656) and the Cluster of Excellence, Cells-in-Motion (CiM), of which Partner 8 is the spokesperson. The group of partner has contributed significantly to the structural and functional characterization cerebral blood vessels and mechanisms of immune cell migration into the brain.

Roles and tasks of WWU in SVDs@target

WWU will lead WP4 (Inflammatory mechanisms: immune cell binding and transmigration in SVDs) and will contribute to WP2 (Blood brain barrier integrity and perivascular flow), WP3 (Microvascular matrisome and vascular integrity) and WP5 (Validation of mechanisms through interventions).

 

 

Key staff

Prof. Lydia Sorokin
Prof. Lydia Sorokin

Full Professor and Director of Physiological Chemistry and Pathobiochemisty (W3), Münster University, Münster, Germany;
Spokesperson of the Cells-in-Motion Cluster of Excellence, University of Münster;
Member of the North Rhein-Westphalian Academy of Sciences, Humanities & Arts;
External Advisory Board member of the University of Cologne, Center for Molecular Medicine (ZMMK);
Scientific Steering Committee member of CRC Transregio 128 - Multiple Sclerosis;
Chair of the external advisory Board,  Max-Planck Institute for Medical Research, Heidelberg, Germany.
External Advisory Board, Interdisciplinary Centre for Clinical Research (IZKF), University of Erlangen-Nürnberg, Germany.
Elected Member, DFG panel ‘Basic Principles of Biology and Medicine’

Prof. Sorokin is a work package leader (WP4) in SVDs@target.



SVD@target team at WWU

Dr. Tushar Deshpande

Dr. Tushar Deshpande is a non-clinical pharmacologist by training with a broad interest in various neuropathologies and therapeutic strategies thereof. He is investigating the role of inflammation and innate immune system in the pathophysiology of cerebral small vessel diseases.

 

Dr. Jula Huppert

Postdoctoral scientist

Immunologist with experience in ischemic stroke models and confocal microscopy of brain slices.

 

Search
Home
Menu
Top

Tweets by SVDS@target

Publications with PubMed ID

Authors: Ratelade J, Klug NR, Lombardi D, Angelim MKSC, Dabertrand F, Domenga-Denier V, Al-Shahi Salman R, Smith C, Gerbeau JF, Nelson MT, Joutel A

Circulation. 2020 Mar 18;

PMID: 32183562

Authors: Li Q, Aalling NN, Förstera B, Ertürk A, Nedergaard M, Møllgård K, Xavier ALR

Fluids and barriers of the CNS. 2020 Feb 11;17(1):15

PMID: 32046744    Open Access: PMC7014736

Authors: Georgakis MK, Malik R, Anderson CD, Parhofer KG, Hopewell JC, Dichgans M

Brain : a journal of neurology. 2020 Feb 1;143(2):597-610

PMID: 31968102    Open Access: PMC7009571

Authors: Sloots JJ, Biessels GJ, Zwanenburg JJM

NeuroImage. 2020 Apr 15;210:116581

PMID: 31982580

Authors: Mestre H, Du T, Sweeney AM, Liu G, Samson AJ, Peng W, Mortensen KN, Stæger FF, Bork PAR, Bashford L, Toro ER, Tithof J, Kelley DH, Thomas JH, Hjorth PG, Martens EA, Mehta RI, Solis O, Blinder P, Kleinfeld D, Hirase H, Mori Y, Nedergaard M

Science (New York, N.Y.). 2020 Mar 13;367(6483)

PMID: 32001524

Authors: Abraham G, Malik R, Yonova-Doing E, Salim A, Wang T, Danesh J, Butterworth AS, Howson JMM, Inouye M, Dichgans M

Nature communications. 2019 Dec 20;10(1):5819

PMID: 31862893    Open Access: PMC6925280